Shares of Amarin Corp. nearly doubled today on positive data from its cholesterol drug and renewed speculation that the company could be a big pharma takeover target.
AMRN stock price printed a closing quote of $17.10 a gain of $8.33 (95.03%).
Amarin reported positive news that its cholesterol treatment, an omega-3 compound named AMR101, lowered triglyceride levels without increasing bad cholesterol in study patients.
The blockbuster potential of AMR101 has fueled speculation and rumors throughout the biotech and drug sector that Amarin could be the next takeover target for a big pharma company.
Amarin currently has a market capitalization of $1.83 billion and AMRN stock price is up from a 52 week low of $1.62 a share.
Amarin stock AMRN
